CONTINEUM THERAPEUTICS INC CLASS A (CTNM) — insider trading
Health Care · NASDAQ
CONTINEUM THERAPEUTICS INC CLASS A (CTNM) has 31 reported SEC Form 4 insider transactions in our data, including 8 open-market sales among the most recent 31 (latest 2026-07-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-09 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 25 | $0.00 | $0 | Form 4 |
| 2026-07-09 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Open-market sale | 25 | $16.00 | $400 | Form 4 |
| 2026-07-09 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion | 25 | $1.01 | $25 | Form 4 |
| 2026-07-08 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 1,015 | $0.00 | $0 | Form 4 |
| 2026-07-08 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Open-market sale | 1,015 | $16.00 | $16.2K | Form 4 |
| 2026-07-08 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion | 1,015 | $1.01 | $1.0K | Form 4 |
| 2026-07-08 | Stengone Carmine N. | Director, Officer (CEO and President) | Option exercise / conversion (derivative) | 2,500 | $0.00 | $0 | Form 4 |
| 2026-07-08 | Stengone Carmine N. | Director, Officer (CEO and President) | Open-market sale | 2,500 | $16.00 | $40.0K | Form 4 |
| 2026-07-08 | Stengone Carmine N. | Director, Officer (CEO and President) | Option exercise / conversion | 2,500 | $1.01 | $2.5K | Form 4 |
| 2026-07-01 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 4,183 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Open-market sale | 2,501 | $16.24 | $40.6K | Form 4 |
| 2026-07-01 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Open-market sale | 5,852 | $15.67 | $91.7K | Form 4 |
| 2026-07-01 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion | 4,183 | $1.01 | $4.2K | Form 4 |
| 2026-06-30 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 28,826 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Open-market sale | 28,826 | $16.04 | $462.3K | Form 4 |
| 2026-06-30 | Lorrain Daniel S. | Officer (Chief Scientific Officer) | Option exercise / conversion | 28,826 | $1.01 | $29.1K | Form 4 |
| 2026-06-30 | Stengone Carmine N. | Director, Officer (CEO and President) | Option exercise / conversion (derivative) | 2,500 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Stengone Carmine N. | Director, Officer (CEO and President) | Option exercise / conversion (derivative) | 7,500 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Stengone Carmine N. | Director, Officer (CEO and President) | Open-market sale | 10,000 | $16.01 | $160.1K | Form 4 |
| 2026-06-30 | Stengone Carmine N. | Director, Officer (CEO and President) | Option exercise / conversion | 2,500 | $1.26 | $3.1K | Form 4 |
| 2026-06-30 | Stengone Carmine N. | Director, Officer (CEO and President) | Option exercise / conversion | 7,500 | $1.01 | $7.6K | Form 4 |
| 2026-06-30 | Watkins Tim | Officer (CMO & Head of Development) | Option exercise / conversion (derivative) | 10,833 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Watkins Tim | Officer (CMO & Head of Development) | Open-market sale | 10,833 | $16.02 | $173.6K | Form 4 |
| 2026-06-30 | Watkins Tim | Officer (CMO & Head of Development) | Option exercise / conversion | 10,833 | $4.50 | $48.7K | Form 4 |
| 2026-06-26 | Boyce Sarah | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Brady Todd R. | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Ignelzi Troy A. | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Schimmelpennink Evert B. | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Ware Olivia C | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Lyons-Williams Lori | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Miralles Gines Diego | Director | Grant / award / vesting (derivative) | 19,000 | $0.00 | $0 | Form 4 |
Ask the chat about CTNM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CONTINEUM THERAPEUTICS INC CLASS A (CTNM).
Last updated 2026-07-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.